Royalty Pharma
RPRX | NASDAQ
$58.53
+$0.09 (+0.15%)
Sep 22, 2026, 12:47 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 2.38B | 2.26B | 2.35B | 2.24B | 2.29B | 2.12B |
Operating Income | 1.56B | 1.29B | 1.49B | 307.07M | 1.43B | 1.6B |
Interest Income | 33.59M | 47.34M | 72.29M | 78.34M | 53.54M | 28.38M |
Pretax Income | 1.32B | 1.33B | 1.7B | 230.06M | 1.24B | 1.7B |
Net Income | 770.95M | 858.98M | 1.13B | 42.83M | 619.73M | 975.04M |
Selling & General & Admin | 573.48M | 236.67M | 249.75M | 227.3M | 182.83M | 181.72M |
Research & Development | 452M | 2M | 52M | 177.11M | 200.08M | 26.29M |
Other Expenses | -206.81M | 732.46M | 560.66M | 1.53B | 475.84M | 318.95M |
Operating Expenses | 818.68M | 971.13M | 862.4M | 1.93B | 858.75M | 526.95M |
Interest Expense | 307.66M | 225.51M | 187.19M | 187.96M | 166.14M | 157.06M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 818.68M | 971.13M | 862.4M | 1.93B | 858.75M | 526.95M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 431.89M | 445.99M | 447.6M | 437.96M | 414.79M | 388.14M |
Shares Outstanding (Diluted) | 559.61M | 594M | 602.9M | 564.93M | 414.8M | 388.14M |
EPS (Basic) | 2.33 | 1.92 | 3.41 | 0.10 | 1.49 | 1.28 |
EPS (Diluted) | 1.80 | 1.91 | 2.53 | 0.10 | 1.49 | 1.28 |
EBITDA | 1.64B | 1.56B | 1.89B | 423.7M | 1.43B | 1.88B |
EBIT | 1.63B | 1.56B | 1.89B | 418.03M | 1.41B | 1.86B |
Depreciation & Amortization | 3.85M | n/a | n/a | 5.67M | 23M | 23.06M |
Add to Watchlist
Select watchlists to add or remove RPRX